04Sep 2023
Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD)

Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD)

A recent study, the CLEAN-PCD trial, has shown promising results for individuals with primary ciliary dyskinesia (PCD). Researchers tested the efficacy of idrevloride, an epithelial sodium channel (ENaC) blocker, in combination with hypertonic saline for improving lung function in PCD patients. The trial involved 123 participants and found that idrevloride in hypertonic saline led to significant improvements in lung function compared to hypertonic saline alone. Adverse events were comparable across treatments, with cough being more prevalent in idrevloride or hypertonic saline groups. This study suggests potential benefits for PCD patients and calls for further, larger-scale investigations.

  • #pulmonology

Like

Save

Share